To assess whether the administration of EQ alone or combined with CIS can overcome the adverse effects of CIS when given alone, we evaluated the changes in some hematological parameters (Hb content and RBC, WBC, and PLT count). This evidence concerns the gene GSTM1 and in situ carcinoma.